ORTATAXEL

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C44H57NO17
Molecular Weight	871.9199
Optical Activity	UNSPECIFIED
Defined Stereocenters	12 / 12
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@H](NC(=O)OC(C)(C)C)[C@@H](O)C(=O)O[C@H]1[C@@H]2OC(=O)O[C@@]23[C@@H](OC(=O)C4=CC=CC=C4)[C@@H]5[C@@]6(CO[C@@H]6C[C@H](O)[C@@]5(C)C(=O)[C@H](OC(C)=O)C(=C1C)C3(C)C)OC(C)=O

InChI

InChIKey=BWKDAMBGCPRVPI-ZQRPHVBESA-N

InChI=1S/C44H57NO17/c1-20(2)17-25(45-38(53)61-40(6,7)8)29(49)37(52)57-30-21(3)28-31(56-22(4)46)33(50)42(11)26(48)18-27-43(19-55-27,60-23(5)47)32(42)35(58-36(51)24-15-13-12-14-16-24)44(41(28,9)10)34(30)59-39(54)62-44/h12-16,20,25-27,29-32,34-35,48-49H,17-19H2,1-11H3,(H,45,53)/t25-,26-,27+,29+,30+,31+,32-,34-,35-,42+,43-,44+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C44H57NO17
Molecular Weight	871.9199
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	12 / 12
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00044538 | https://www.ncbi.nlm.nih.gov/pubmed/30726533 | https://clinicaltrials.gov/ct2/show/NCT00054314 | https://clinicaltrials.gov/ct2/show/NCT00044538

Ortataxel (previously known as IDN 5109 or BAY59-8862), a second-generation taxane derivative that was developed as an antitumor agent. Ortataxel binds to and stabilizes tubulin molecules, thereby interfering with the dynamics of microtubule assembly/disassembly. This results in the inhibition of cell division and cellular proliferation. In addition, ortataxel modulates multi-drug resistance mechanisms and may be useful for treating multi-drug resistant tumors that express Pgp, MRP-1, and BCRP. This drug participated in phase II clinical trials in patients with advanced renal cell carcinoma and in patients with Non-Hodgkin's lymphoma. However, these studies were discontinued. Ortataxel was also involved in phase II clinical trials for patients with glioblastoma; however, in a limited number of patients, the drug produced a benefit that lasted for a long time. Besides, ortataxel successfully completed phase II trials in taxane-resistant metastatic breast cancer patients and in taxane-resistant non-small cell lung cancer patients.

Approval Year

PubMed

Title	Date	PubMed
Antitumor effects of IDN5109 on head and neck squamous cell carcinoma.	2006-02	16391850
Oral efficacy and bioavailability of a novel taxane.	2000-05	10815934
IDN5109, a taxane with oral bioavailability and potent antitumor activity.	2000-02-15	10706091
Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells.	1997-09-04	9311603

Sample Use Guides

In Vivo Use Guide

Intravenous dose over 60 minutes every 3 weeks

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:36 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:36 GMT 2025`
Record UNII	8H61Y4E29N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ORTATAXEL

Official Name

English

BAY 59-8862

Preferred Name

English

IDN-5109

Code

English

SB-T 101131

Code

English

Ortataxel [WHO-DD]

Common Name

English

BAY-59-8862

Code

English

IDN5109

Code

English

SB-T-101131

Code

English

ortataxel [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67437